Bonell Patiño E
@bonellpatinoe.bsky.social
MD. IM/Hematology #IMG🇨🇴. Amateur musician. Soda Stereo/Cerati Fan. Postdoc at @ucsf 🇺🇸. MMRF fellow. Interested in #Myeloma #CART and NK cell adoptive cell therapies. RStudio, Python, and ML-AI enthusiast
Reposted by Bonell Patiño E
Here cytokine receptor domains have been repurposed to develop engineered T cells that can sense and respond to cues associated with cancer or immune dysfunction
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Conversion of natural cytokine receptors into orthogonal synthetic biosensors - Nature Chemical Biology
Synthetic receptors are a powerful approach for engineering cell-based therapies that can sense and respond to their environment. Here cytokine receptor domains have been repurposed to develop enginee...
www.nature.com
August 26, 2025 at 3:54 PM
Here cytokine receptor domains have been repurposed to develop engineered T cells that can sense and respond to cues associated with cancer or immune dysfunction
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Bonell Patiño E
In Brief: A new center in San Francisco will offer tailor-made CRISPR therapies to cure children with rare diseases www.nature.com/articles/s41...
Children with rare genetic diseases get CRISPR Cures center - Nature Biotechnology
Nature Biotechnology - Children with rare genetic diseases get CRISPR Cures center
www.nature.com
August 26, 2025 at 4:04 PM
In Brief: A new center in San Francisco will offer tailor-made CRISPR therapies to cure children with rare diseases www.nature.com/articles/s41...
Reposted by Bonell Patiño E
Special shout-out to our Junior Specialist Sanjana Prudhvi, who designed our Visual Abstract. We are lucky to work with such an amazing team, including everyone in the Wiita Lab @ucsfcancer.bsky.social and our collaborators. (10/10)
August 25, 2025 at 3:25 PM
Special shout-out to our Junior Specialist Sanjana Prudhvi, who designed our Visual Abstract. We are lucky to work with such an amazing team, including everyone in the Wiita Lab @ucsfcancer.bsky.social and our collaborators. (10/10)
Reposted by Bonell Patiño E
Finally, we developed a proof-of-principle dual-targeting CAR against both BCMA and CD70 as a potential strategy to avoid antigen escape–mediated resistance in #HRMM (9/10)
August 25, 2025 at 3:25 PM
Finally, we developed a proof-of-principle dual-targeting CAR against both BCMA and CD70 as a potential strategy to avoid antigen escape–mediated resistance in #HRMM (9/10)
Reposted by Bonell Patiño E
We also evaluated epigenetic regulation of CD70 in #myeloma, using a machine learning model to predict and then test key transcriptional regulators of surface expression (8/10)
August 25, 2025 at 3:25 PM
We also evaluated epigenetic regulation of CD70 in #myeloma, using a machine learning model to predict and then test key transcriptional regulators of surface expression (8/10)
Reposted by Bonell Patiño E
While all anti-CD70 CARs demonstrated clear efficacy against myeloma cell line xenograft models in vivo, the CD27-based CAR showed remarkable >80-fold expansion‼️ versus scFv-based CARs, suggesting a highly favorable phenotype for clinical translation (7/10)
August 25, 2025 at 3:25 PM
While all anti-CD70 CARs demonstrated clear efficacy against myeloma cell line xenograft models in vivo, the CD27-based CAR showed remarkable >80-fold expansion‼️ versus scFv-based CARs, suggesting a highly favorable phenotype for clinical translation (7/10)
Reposted by Bonell Patiño E
We then used the crystal structure of CD70 bound to its natural receptor CD27 to develop a structure-guided, optimized CD27-based CAR to compare to standard “scFv” based CAR, using frameworks containing either CD28 or 4-1BB costim domains. (6/10)
August 25, 2025 at 3:25 PM
We then used the crystal structure of CD70 bound to its natural receptor CD27 to develop a structure-guided, optimized CD27-based CAR to compare to standard “scFv” based CAR, using frameworks containing either CD28 or 4-1BB costim domains. (6/10)
Reposted by Bonell Patiño E
Analysis of paired tumor RNA sequencing data from
@themmrf.bsky.social CoMMpass study, cell surface #proteomics, and flow cytometry revealed CD70 was present on primary #myeloma. CD70 transcript was strongly enriched in high risk genotypes t(4;14), gain 1q, and loss 1p (5/10)
@themmrf.bsky.social CoMMpass study, cell surface #proteomics, and flow cytometry revealed CD70 was present on primary #myeloma. CD70 transcript was strongly enriched in high risk genotypes t(4;14), gain 1q, and loss 1p (5/10)
August 25, 2025 at 3:25 PM
Analysis of paired tumor RNA sequencing data from
@themmrf.bsky.social CoMMpass study, cell surface #proteomics, and flow cytometry revealed CD70 was present on primary #myeloma. CD70 transcript was strongly enriched in high risk genotypes t(4;14), gain 1q, and loss 1p (5/10)
@themmrf.bsky.social CoMMpass study, cell surface #proteomics, and flow cytometry revealed CD70 was present on primary #myeloma. CD70 transcript was strongly enriched in high risk genotypes t(4;14), gain 1q, and loss 1p (5/10)
Reposted by Bonell Patiño E
...Samir Parekh at Icahn Mount Sinai, Stieglitz lab and the myeloma clinical group @ucsfcancer.bsky.social . Major support from Myeloma Solutions Fund, NIH NCI, and
UCSF Living Therapeutics Initiative (4/10)
UCSF Living Therapeutics Initiative (4/10)
August 25, 2025 at 3:25 PM
...Samir Parekh at Icahn Mount Sinai, Stieglitz lab and the myeloma clinical group @ucsfcancer.bsky.social . Major support from Myeloma Solutions Fund, NIH NCI, and
UCSF Living Therapeutics Initiative (4/10)
UCSF Living Therapeutics Initiative (4/10)
Reposted by Bonell Patiño E
This work was co-led by myself, Adila Izgutdina, and
@bonellpatinoe.bsky.social under mentorship of @apwiita.bsky.social, + collab w/ Ben Barwick and Larry Boise @winshipcancer.emory.edu, @jdlicht.bsky.social,
@shanmugamlab.bsky.sociall, @kortemmelab.bsky.social, and... (3/10)
@bonellpatinoe.bsky.social under mentorship of @apwiita.bsky.social, + collab w/ Ben Barwick and Larry Boise @winshipcancer.emory.edu, @jdlicht.bsky.social,
@shanmugamlab.bsky.sociall, @kortemmelab.bsky.social, and... (3/10)
August 25, 2025 at 3:25 PM
This work was co-led by myself, Adila Izgutdina, and
@bonellpatinoe.bsky.social under mentorship of @apwiita.bsky.social, + collab w/ Ben Barwick and Larry Boise @winshipcancer.emory.edu, @jdlicht.bsky.social,
@shanmugamlab.bsky.sociall, @kortemmelab.bsky.social, and... (3/10)
@bonellpatinoe.bsky.social under mentorship of @apwiita.bsky.social, + collab w/ Ben Barwick and Larry Boise @winshipcancer.emory.edu, @jdlicht.bsky.social,
@shanmugamlab.bsky.sociall, @kortemmelab.bsky.social, and... (3/10)
Reposted by Bonell Patiño E
In this work we show CD70 is a novel CAR target enriched in #HRMM. We used structure-guided design to optimize a CD27-based anti-CD70 CAR-T that outperforms scFv-based CAR-Ts in preclinical efficacy studies. (2/10)
August 25, 2025 at 3:25 PM
In this work we show CD70 is a novel CAR target enriched in #HRMM. We used structure-guided design to optimize a CD27-based anti-CD70 CAR-T that outperforms scFv-based CAR-Ts in preclinical efficacy studies. (2/10)
Reposted by Bonell Patiño E
Excited to share our new manuscript, now published in Blood! BCMA #CART show impressive responses for #myeloma, but pts with high-risk cytogenetics relapse more quickly and are in urgent need of new therapies. Thread👇 (1/10) ashpublications.org/blood/articl...
August 25, 2025 at 3:25 PM
Excited to share our new manuscript, now published in Blood! BCMA #CART show impressive responses for #myeloma, but pts with high-risk cytogenetics relapse more quickly and are in urgent need of new therapies. Thread👇 (1/10) ashpublications.org/blood/articl...
Reposted by Bonell Patiño E
Excited that the paper presenting our mouse brain in vivo CRISPR screening platform is out today in @natneuro.nature.com!
Great team effort, led by Biswa Ramani and @ivlrose.bsky.social in the Kampmann lab.
www.nature.com/articles/s41...
Great team effort, led by Biswa Ramani and @ivlrose.bsky.social in the Kampmann lab.
www.nature.com/articles/s41...
CRISPR screening by AAV episome-sequencing (CrAAVe-seq): a scalable cell-type-specific in vivo platform uncovers neuronal essential genes - Nature Neuroscience
The authors developed an adeno-associated virus-based high-throughput in vivo CRISPR screening platform for endogenous mouse brain cell types. Using this platform, they define genes and pathways essen...
www.nature.com
August 22, 2025 at 10:15 PM
Excited that the paper presenting our mouse brain in vivo CRISPR screening platform is out today in @natneuro.nature.com!
Great team effort, led by Biswa Ramani and @ivlrose.bsky.social in the Kampmann lab.
www.nature.com/articles/s41...
Great team effort, led by Biswa Ramani and @ivlrose.bsky.social in the Kampmann lab.
www.nature.com/articles/s41...
Thrilled to share our new paper in Blood! We show that CD70 is upregulated in high-risk MM, and that a CD27-based anti-CD70 CAR-T design achieves >80-fold improved expansion in vivo. So honored to co–lead this work with @corynnkasap.bsky.social, Adila Izgutdina under
@apwiita.bsky.social mentorship
@apwiita.bsky.social mentorship
August 18, 2025 at 6:06 AM
Thrilled to share our new paper in Blood! We show that CD70 is upregulated in high-risk MM, and that a CD27-based anti-CD70 CAR-T design achieves >80-fold improved expansion in vivo. So honored to co–lead this work with @corynnkasap.bsky.social, Adila Izgutdina under
@apwiita.bsky.social mentorship
@apwiita.bsky.social mentorship
Reposted by Bonell Patiño E
A programmable RNA acetylation system using dCas13-eNAT10 is developed to install N4-acetylcytidine on target RNAs in cells and in vivo, enabling functional studies of RNA acetylation and revealing the unique role of RNA acetylation in transcript localization
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Programmable RNA acetylation with CRISPR–Cas13 - Nature Chemical Biology
Yu et al. developed a programmable RNA acetylation system using dCas13–eNAT10 to specifically install N4-acetylcytidine on target RNAs in cells and in vivo, enabling functional studies of RNA acetylat...
www.nature.com
June 3, 2025 at 8:29 PM
A programmable RNA acetylation system using dCas13-eNAT10 is developed to install N4-acetylcytidine on target RNAs in cells and in vivo, enabling functional studies of RNA acetylation and revealing the unique role of RNA acetylation in transcript localization
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Bonell Patiño E
The clinical application of CAR T cell therapy remains limited owing to off-target toxicity. This article discusses the remote and spatiotemporal control of CAR T cells by combining stimuli-responsive nanotechnologies with immunoengineering:
Remote control of cellular immunotherapy - Nature Reviews Bioengineering
Chimeric antigen receptor (CAR) T cell activities can be remotely controlled to provide spatiotemporal precision of CAR T cell activity and improve the safety of cellular immunotherapies. This Review discusses physical and chemogenetic stimuli and the combination of stimuli-responsive nanotechnologies with immuno-engineering to design controllable CAR T cell therapies.
go.nature.com
May 24, 2025 at 2:04 PM
The clinical application of CAR T cell therapy remains limited owing to off-target toxicity. This article discusses the remote and spatiotemporal control of CAR T cells by combining stimuli-responsive nanotechnologies with immunoengineering:
Reposted by Bonell Patiño E
Many with sleep apnea aren’t adequately treated because they find continuous positive airway pressure machines too burdensome. A new pill may offer an alternative.
Sleep apnea pill shows striking success in large clinical trial
Drug combination targeting lax airways is nearing an FDA submission
scim.ag
May 24, 2025 at 2:07 PM
Many with sleep apnea aren’t adequately treated because they find continuous positive airway pressure machines too burdensome. A new pill may offer an alternative.
With CD22-targeting CAR-T cells faltering, CD72 clearly stands out as the next big target. Proud to have contributed to Adila Izgutdina and amazing team’s preprint showing that our CD72 nanoCAR outperforms CD22 in CD19-refractory B-ALL and B-NHL. Excited for the Phase I trial at UCSF in 2026!
‼️Preprint‼️ CD22 CAR Ts are cooked - time to move on to CD72. Adila Izgutdina and fantastic collaborators show CD72 is likely a better second-line antigen than CD22 for CD19-refractory B-ALL/B-NHL. Excited to bring CD72 “nanoCARs” to the clinic @ucsfhealth.bsky.social. www.biorxiv.org/content/10.1...
Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell Malignancies
Background: Chimeric antigen receptor (CAR) T-cell therapies are highly efficacious for several different hematologic cancers. However, for most CAR T targets it is observed that low surface antigen d...
www.biorxiv.org
May 17, 2025 at 4:38 AM
With CD22-targeting CAR-T cells faltering, CD72 clearly stands out as the next big target. Proud to have contributed to Adila Izgutdina and amazing team’s preprint showing that our CD72 nanoCAR outperforms CD22 in CD19-refractory B-ALL and B-NHL. Excited for the Phase I trial at UCSF in 2026!
Reposted by Bonell Patiño E
‼️Preprint‼️ CD22 CAR Ts are cooked - time to move on to CD72. Adila Izgutdina and fantastic collaborators show CD72 is likely a better second-line antigen than CD22 for CD19-refractory B-ALL/B-NHL. Excited to bring CD72 “nanoCARs” to the clinic @ucsfhealth.bsky.social. www.biorxiv.org/content/10.1...
Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell Malignancies
Background: Chimeric antigen receptor (CAR) T-cell therapies are highly efficacious for several different hematologic cancers. However, for most CAR T targets it is observed that low surface antigen d...
www.biorxiv.org
May 16, 2025 at 4:17 PM
‼️Preprint‼️ CD22 CAR Ts are cooked - time to move on to CD72. Adila Izgutdina and fantastic collaborators show CD72 is likely a better second-line antigen than CD22 for CD19-refractory B-ALL/B-NHL. Excited to bring CD72 “nanoCARs” to the clinic @ucsfhealth.bsky.social. www.biorxiv.org/content/10.1...
Reposted by Bonell Patiño E
Salvage autologous transplant vs lenalidomide/dexamethasone offers no significant survival benefit in RRMM. buff.ly/vq0OGYy #hemesky #clinicaltrialsandobservations
April 22, 2025 at 2:03 PM
Salvage autologous transplant vs lenalidomide/dexamethasone offers no significant survival benefit in RRMM. buff.ly/vq0OGYy #hemesky #clinicaltrialsandobservations
Reposted by Bonell Patiño E
Researchers are studying why mitochondria are moving between cells and whether the process can be harnessed to treat cancer and other diseases
https://go.nature.com/3RcyzDa
https://go.nature.com/3RcyzDa
Cells are swapping their mitochondria. What does this mean for our health?
Nature - Researchers are studying why the energy factories are moving between cells and whether the process can be harnessed to treat cancer and other diseases.
go.nature.com
April 13, 2025 at 4:16 PM
Researchers are studying why mitochondria are moving between cells and whether the process can be harnessed to treat cancer and other diseases
https://go.nature.com/3RcyzDa
https://go.nature.com/3RcyzDa
Advancing target discovery is key to developing safer and more effective immune-cellular therapies.
Innovative new technologies are redefining the treatment of hematologic malignancies: https://bit.ly/4hBJPoj
@bonellpatinoe.bsky.social
#Hematology #HemeSky #BloodSky
2/4
@bonellpatinoe.bsky.social
#Hematology #HemeSky #BloodSky
2/4
February 17, 2025 at 4:31 AM
Advancing target discovery is key to developing safer and more effective immune-cellular therapies.
Reposted by Bonell Patiño E
Innovative new technologies are redefining the treatment of hematologic malignancies: https://bit.ly/4hBJPoj
@bonellpatinoe.bsky.social
#Hematology #HemeSky #BloodSky
2/4
@bonellpatinoe.bsky.social
#Hematology #HemeSky #BloodSky
2/4
February 16, 2025 at 9:48 PM
Innovative new technologies are redefining the treatment of hematologic malignancies: https://bit.ly/4hBJPoj
@bonellpatinoe.bsky.social
#Hematology #HemeSky #BloodSky
2/4
@bonellpatinoe.bsky.social
#Hematology #HemeSky #BloodSky
2/4
Reposted by Bonell Patiño E
#REVIEW 🚨
In our latest review, Eyelet Erez & colleagues examine the complex interactions among tumors, the microenvironment & the host. They outline how this crosstalk impacts metastasis, inflammation & cachexia, providing insights for enhanced cancer management.
Read it here now 👇
bit.ly/3DW7Kj9
In our latest review, Eyelet Erez & colleagues examine the complex interactions among tumors, the microenvironment & the host. They outline how this crosstalk impacts metastasis, inflammation & cachexia, providing insights for enhanced cancer management.
Read it here now 👇
bit.ly/3DW7Kj9
Metabolic interplays between the tumour and the host shape the tumour macroenvironment - Nature Reviews Cancer
In this Review, Erez and colleagues examine the complex interactions among tumours, their microenvironment and the host, shaping a metabolic macroenvironment that drives cancer progression. They explo...
bit.ly
January 24, 2025 at 2:01 PM
#REVIEW 🚨
In our latest review, Eyelet Erez & colleagues examine the complex interactions among tumors, the microenvironment & the host. They outline how this crosstalk impacts metastasis, inflammation & cachexia, providing insights for enhanced cancer management.
Read it here now 👇
bit.ly/3DW7Kj9
In our latest review, Eyelet Erez & colleagues examine the complex interactions among tumors, the microenvironment & the host. They outline how this crosstalk impacts metastasis, inflammation & cachexia, providing insights for enhanced cancer management.
Read it here now 👇
bit.ly/3DW7Kj9